Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer

PHASE3CompletedINTERVENTIONAL

Enrollment

136

Participants

Timeline

Start Date

August 27, 2021

Primary Completion Date

June 23, 2023

Study Completion Date

May 5, 2025

Conditions

Prostate CancerProstate Cancer Recurrent

Interventions

DRUG

[18F]PSMA-1007

diagnostic radiopharmaceutical for PET scan

Trial Locations (6)

Mayo Clinic, Rochester

MD Anderson Cancer Center, Houston

Excel Diagnostics and Nuclear Oncology Center, Houston

Huntsman Cancer Institute, Salt Lake City

RUMC, Nijmegen

Inselspital, Universitätsspital, Bern

All Listed Sponsors

lead

ABX advanced biochemical compounds GmbH

INDUSTRY

NCT04742361 - Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer | Biotech Hunter | Biotech Hunter